Gossamer targets September 2026 seralutinib NDA filing with potential Q3 2027 approval (NASDAQ:GOSS)


Earnings Call Insights: Gossamer Bio (GOSS) Q1 2026

Management View

  • CEO Faheem Hasnain framed PROSERA’s topline as clinically meaningful but statistically mixed: “PROSERA showed a clinically meaningful placebo-adjusted improvement of 13.3 meters in 6-minute walk distance at week 24, with patients on

Seeking Alpha’s Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.



Source link

How I ensure my Blu-ray collection will outlive me

Papoose & Internet Reacts To Dance Video

Leave a Reply

Your email address will not be published. Required fields are marked *